CVS HEALTH Q3 2026 EARNINGS CONFERENCE CALL - CVS HEALTH CORP

Financial Performance:

• Third quarter 2026 revenue exceeded $108 billion; adjusted operating income reached $4.2 billion.
• Adjusted EPS was $2.09, representing a >30% year-over-year increase.
• Cash flow from operations (CFO) for the quarter was approximately $4.7 billion, bringing YTD CFO to $15.3 billion.
• Segment performance: Health Care Benefits adjusted operating income was ~$900 million (+$600M YoY) with a Medical Benefit Ratio (MBR) of 91.3% (-150 bps YoY); Health Services adjusted operating income was $2.1 billion (+3% YoY); Pharmacy and Consumer Wellness adjusted operating income was >$1.6 billion (+10% YoY).
• Shareholder returns included nearly $2.6 billion in dividends in 2026; the company expects to resume share repurchases in Q4 2026.

Guidance and Future Outlook:

• 2026 Adjusted EPS guidance raised to at least $8.20 (previously $7.90–$8.10); 2026 Total Revenue guidance raised to at least $420 billion.
• 2026 Cash flow from operations guidance raised to at least $15.5 billion; Enterprise Adjusted Operating Income guidance raised to at least $17.05 billion.
• 2027 Adjusted EPS guidance set at a floor of $8.65, implying ~13% growth over the revised 2026 baseline.
• Long-term goal: Achieve a mid-teens (upper end) adjusted EPS CAGR through 2028.
• Headwinds for 2027 include a decline in the 340B business and health plan client membership attrition; tailwinds include specialty strength and healthcare delivery improvements.
• 2028 expectations for 340B business stabilization and return to growth for the Health Services segment.

Business Segments and Product Lines:

• Strategic Separation: Announced plan to split into two independent public companies: CVS Health (Healthcare Solutions) and CVS Pharmacy (Retail Pharmacy).
• CVS Health (Remaining Co): Will include Aetna, Caremark, Pharmacy Services, Specialty Pharmacy, Oak Street, and Signify Health; focused on medical/pharmacy integration, high-acuity care, and affordability.
• CVS Pharmacy (New Co): Will include retail stores, mail order, MinuteClinic, and HealthH100; led by Group President Prem Shah; focused on community health and consumer engagement.
• 340B Business: Expecting year-over-year decline in 2027 but confident in stabilization by end of 2027 and robust pipeline for the 2028 selling season.
• Medicare Advantage: On track to return to profitability in 2026, with targeted margin improvement expected in 2027.
• Retail Pharmacy: Experienced 3.9% comp script growth; GLP-1 scripts grew 23% in Q3; AI now supports 85% of pharmacy workflows.

Market and Competitive Landscape:

• Healthcare environment characterized by elevated medical cost trends persisting through 2027.
• CVS Health views the separation as a move to enhance agility and capitalize on technology (AI) and interoperability.
• CVS Pharmacy positions itself as the most trusted consumer touchpoint in a >$500B market, leveraging its footprint to standardize care and address affordability.
• Specialty pharmacy remains a critical lever for managing the 2% of the population driving >50% of pharmacy spend.

Risks and Challenges:

• Execution risks associated with the separation transaction, including potential one-time costs and stranded operating costs (anticipated to be manageable and offset by synergy).
• Regulatory and legislative headwinds impacting the 340B program and pharmacy rebates.
• Persistent elevated medical cost trends in the healthcare benefits segment.
• Membership attrition from strategic decisions by health plan clients in the pharmacy services business.
• Market dynamics regarding GLP-1 pricing and access remain a focus area for consumer dynamics.

Management Commentary and Tone:

• Management tone is confident and assertive, emphasizing the decision is made from a "position of strength" rather than distress.
• David Joyner (CEO) highlighted 20 years of evolution and the company's "say-do" ratio of delivering on commitments over the last eight quarters.
• Emphasis on "integration where it matters" (medical, pharmacy, and care delivery) versus "arm's length" negotiations for retail components.
• Commitment to maintaining investment-grade balance sheets for both post-separation entities with tailored capital allocation.
• HealthH100 (AI-native platform) is positioned as the "connective tissue" and future engagement engine for both companies.

Analyst Questions and Answers:

• Timing/Rationale: Management cited the successful turnaround of the Medicare business and retail growth over the last two years as the catalyst for separating while healthy.
• Balance Sheet: Both entities are expected to maintain solid investment-grade ratings; debt-to-cap metrics will be appropriate for their respective business models; share repurchases to resume Q4 2026.
• 340B Outlook: 2027 is expected to be a trough year with earnings of at least $7B for Health Services; growth expected to return in 2028 with a robust selling season.
• Synergies: Retail mail order will reside with CVS Pharmacy to optimize consumer experience; commercial agreements will maintain strategic alignment between the two entities.
• 2027 EPS: The $8.65 guidance reflects the 2026 guidance upgrade; assumes share repurchase dilution offsets without significant additional accretion in the forecast.
• Medicare Margins: Confirmed moving into profitable territory in 2026 for Medicare Advantage; 2027 will see continued margin expansion.
• Separation Costs: One-time breakup costs and potential run-rate cost increases are considered manageable and expected to be offset by long-term value creation.

Other Key Points:

• Separation transaction is expected to be tax-free and complete in the first half of 2028, subject to regulatory and Board approvals.
• Shareholders will own stock in both CVS Health and CVS Pharmacy upon separation.
• HealthH100 platform will continue to be developed by both companies to democratize data and improve consumer interoperability.
• Prem Shah will transition from Group President to CEO of the new CVS Pharmacy entity.
• The split aims to create two "right to win" organizations with focused leadership teams and simplified structures.